Study: NCT06252870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 15 mg/m² on Day+1 after graft (=Day0) 10 mg/m² 3 days on Day+4/Day+6/Day+11 after graft (=Day0)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: 15 mg/m² on Day+1 after graft (=Day0) 10 mg/m² 3 days on Day+4/Day+6/Day+11 after graft (=Day0)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-Transplant Cyclophosphamide
Description: 50 mg/kg intravenous 2 days on Day+3/Day+5 after graft (=Day0)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Post-Transplant Cyclophosphamide
Description: 50 mg/kg intravenous 2 days on Day+3/Day+5 after graft (=Day0)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Conditioning regimen: 30 mg/m² Intravenous 5 days from Day-6 to Day-2 (Day-6/Day-5-/Day-4/Day-3/Day-2 before graft (=Day0)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cycophosphamide
Description: Conditioning regimen: 14.5 mg/kg intravenous 2 days on Day-6/Day-5 before graft (=Day0)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Thymoglobulin
Description: Conditioning regimen: 2.5 mg/kg intravenous on Day-2 before graft (=Day0)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Thymoglobulin
Description: Conditioning regimen: 2.5 mg/kg intravenous on Day-2 before graft (=Day0)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total body irradiation
Description: 2 grays on Day-1 before graft (=Day0)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hematopoietic stem cells
Description: High dose of hematopoietic stem cells derived from peripheral blood on transplantation day (=Day0 graft)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hematopoietic stem cells
Description: High dose of hematopoietic stem cells derived from peripheral blood on transplantation day (=Day0 graft)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graft nuclear cells
Description: Graft nuclear cells CD3+ cells if needed after transplantation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Graft nuclear cells
Description: Graft nuclear cells CD3+ cells if needed after transplantation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Donor Lymphocytes Injection
Description: DLI with CD3+ if relapse after transplantation or in prevention of relapse

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Donor Lymphocytes Injection
Description: DLI with CD3+ if relapse after transplantation or in prevention of relapse

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Conditioning regimen: 30 mg/m² Intravenous 5 days from Day-6 to Day-2 (Day-6/Day-5-/Day-4/Day-3/Day-2 before graft (=Day0)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiotepa
Description: Conditioning regimen: 5 mg/kg Intravenous at Day-6 before graft (=Day0)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan
Description: Conditioning regimen: 3.2 mg/kg Intravenous 2 days at Day-2 and Day-1 before graft (=Day0)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: Conditioning regimen: 40 mg/m² intravenous 4 days on Day-5/Day-4/Day-3/Day-2 before graft (=Day0)